Merus N.V., an oncology company developing full-length multispecific antibodies and antibody drug conjugates, and Halozyme Therapeutics Inc., a biopharmaceutical company advancing subcutaneous drug delivery solutions, have entered into a global non-exclusive collaboration and license agreement. Under the collaboration, Merus has licensed Halozyme’s ENHANZE drug delivery technology for the development and potential commercialization of subcutaneous administration of petosemtamab, an EGFR...